107 related articles for article (PubMed ID: 36214468)
1. Real-world treatment pattern and prognostic factors of stage IV lung squamous cell carcinoma patients.
Hsu EC; Wu KL; Tsai YM; Lee MH; Tsai MJ; Kuo CY; Liu YC; Liang FW; Yang CJ; Hung JY
Kaohsiung J Med Sci; 2022 Oct; 38(10):1001-1011. PubMed ID: 36214468
[TBL] [Abstract][Full Text] [Related]
2. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B
Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of metastatic patterns and treatment modalities on overall survival in lung squamous cell carcinoma: A population-based study.
Qin L; Yu X; Xu C; Liu Y
Medicine (Baltimore); 2023 Jul; 102(29):e34251. PubMed ID: 37478210
[TBL] [Abstract][Full Text] [Related]
4. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
[TBL] [Abstract][Full Text] [Related]
5. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
Garde-Noguera J; Martin-Martorell P; De Julián M; Perez-Altozano J; Salvador-Coloma C; García-Sanchez J; Insa-Molla A; Martín M; Mielgo-Rubio X; Marin-Liebana S; Blasco-Cordellat A; Blasco-Molla S; Gironés R; Marquez-Medina D; Aparisi F; Cerda MCB; Macia-Escalante S; Sánchez A; Juan-Vidal O
Clin Transl Oncol; 2018 Aug; 20(8):1072-1079. PubMed ID: 29368144
[TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Weiss JM; Pennell N; Deal AM; Morgensztern D; Bradford DS; Crane J; West HJ; Lee C; Pecot C; Stevenson JP; Irvin W; Socinski M; Stinchcombe T; Villaruz LC; Muss HB
Cancer; 2020 Mar; 126(5):1060-1067. PubMed ID: 31943168
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
9. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
10. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
Tambo Y; Sone T; Shibata K; Nishi K; Shirasaki H; Yoneda T; Araya T; Kase K; Nishikawa S; Kimura H; Kasahara K
Clin Lung Cancer; 2020 Sep; 21(5):e366-e379. PubMed ID: 32199806
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
Peters S; Stahel RA; Dafni U; Ponce Aix S; Massutí B; Gautschi O; Coate L; López Martín A; van Heemst R; Berghmans T; Meldgaard P; Cobo Dols M; Garde Noguera J; Curioni-Fontecedro A; Rauch D; Mark MT; Cuffe S; Biesma B; van Henten AMJ; Juan Vidal Ó; Palmero Sanchez R; Villa Guzmán JC; Collado Martin R; Peralta S; Insa A; Summers Y; Láng I; Horgan A; Ciardiello F; de Hosson S; Pieterman R; Groen HJM; van den Berg PM; Zielinski CC; Chittazhathu Kurian Kuruvilla Y; Gasca-Ruchti A; Kassapian M; Novello S; Torri V; Tsourti Z; Gregorc V; Smit EF;
J Thorac Oncol; 2017 Apr; 12(4):752-762. PubMed ID: 28017787
[TBL] [Abstract][Full Text] [Related]
12. [First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute].
Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):8-14. PubMed ID: 24398308
[TBL] [Abstract][Full Text] [Related]
13. Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice.
Ma SC; Bai X; Guo XJ; Liu L; Xiao LS; Lin Y; Tan JL; Cai XT; Wen YX; Ma H; Fu QJ; Leng MX; Zhang YP; Long LL; Guo ZQ; Wu DH; Zhou JG; Dong ZY
BMC Med; 2022 Apr; 20(1):120. PubMed ID: 35410334
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
15. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
Bergqvist M; Christensen HN; Wiklund F; Bergström S
Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
[TBL] [Abstract][Full Text] [Related]
16. Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
Monnet I; Audigier-Valette C; Girard N; Vergnenègre A; Molinier O; Souquet PJ; Blanchon F; Bonnetain F; Taguieva-Pioger N; Lamour C; Wislez M
Lung Cancer; 2016 Aug; 98():84-90. PubMed ID: 27393512
[TBL] [Abstract][Full Text] [Related]
17. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.
Wu XY; Huang XE
Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
[TBL] [Abstract][Full Text] [Related]
19. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic factor analysis of patients with unresectablelung squamous cell carcinoma].
Gao X; Li Z; Shao XY; Liu XM; Liu C; Liu YP; Qu XJ; Zhang LY
Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):569-573. PubMed ID: 34034477
[No Abstract] [Full Text] [Related]
[Next] [New Search]
